Recorded Chinese product: 盐酸奥昔非君片盐酸奥昔非君片
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 北京万辉双鹤药业有限责任公司Chinese legal name: 北京万辉双鹤药业有限责任公司
主要成分Active Ingredients
- 奥营非君Aoying Feijun
药物知识说明
奥营非君是一种在国家药监局注册认定的药品。标注生产企业为北京万辉双鹤药业有限责任公司。
该药品暂无关联的活性成分信息。
该药品标注的生产企业为：北京万辉双鹤药业有限责任公司Chinese legal name: 北京万辉双鹤药业有限责任公司、北京万辉双鹤药业有限责任公司Chinese legal name: 北京万辉双鹤药业有限责任公司、北京万辉双鹤药业有限责任公司Chinese legal name: 北京万辉双鹤药业有限责任公司。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 盐酸奥昔非君片) is a medicine registered with the national drug regulatory authority. It is manufactured by Chinese legal name: 北京万辉双鹤药业有限责任公司.
No active ingredient relationships are currently recorded for this product in MedicineGraph.
Manufacturers recorded for this product: 北京万辉双鹤药业有限责任公司Chinese legal name: 北京万辉双鹤药业有限责任公司, 北京万辉双鹤药业有限责任公司Chinese legal name: 北京万辉双鹤药业有限责任公司, 北京万辉双鹤药业有限责任公司Chinese legal name: 北京万辉双鹤药业有限责任公司.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 盐酸奥昔非君片Recorded Chinese product: 盐酸奥昔非君片
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 4mg4 mg
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
生产企业Manufacturer
- 北京万辉双鹤药业有限责任公司Chinese legal name: 北京万辉双鹤药业有限责任公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H11022057
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H11022057
Manufacturer
Chinese legal name: 北京万辉双鹤药业有限责任公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H11022057
生产企业
北京万辉双鹤药业有限责任公司(国产)
适应症
用于冠心病、心绞痛、心肌梗死。
用法用量
口服。一次4～8g(l～2片)，一日3次(3～6片)。
不良反应
少数患者服用期间可能出现暂时的味觉障碍。
禁忌
对本品过敏者禁用。
注意事项
1.不宜与β受体阻滞剂配伍应用。
2.不能供血流动力学显着改变的主动脉功能不全的患者使用。
贮藏
密封，置阴凉处。
规格
4mg
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.